Antitumor activity in oncology clinical trials is typically assessed using overall survival (OS) or progression-free survival (PFS) endpoints, which are often imprecise and uninformative in small, noncomparative studies. The tumor growth inhibition (TGI) model... ...

请注册登录后继续浏览